Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Nanobiotix    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/21/2020 10/22/2020 10/23/2020 10/26/2020 10/27/2020 Date
6.48(c) 6.53(c) 6.5(c) 6.28(c) 6.03(c) Last
51 310 47 993 61 632 95 185 81 859 Volume
0.00% +0.77% -0.46% -3.38% -3.98% Change
More quotes
Financials
Sales 2020 4,20 M 4,96 M 4,96 M
Net income 2020 -33,4 M -39,4 M -39,4 M
Net Debt 2020 16,1 M 19,0 M 19,0 M
P/E ratio 2020 -3,56x
Yield 2020 -
Sales 2021 3,40 M 4,02 M 4,02 M
Net income 2021 -43,3 M -51,1 M -51,1 M
Net Debt 2021 43,2 M 51,0 M 51,0 M
P/E ratio 2021 -3,35x
Yield 2021 -
Capitalization 163 M 193 M 193 M
EV / Sales 2020 42,7x
EV / Sales 2021 60,8x
Nbr of Employees 98
Free-Float 96,7%
More Financials
Company
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the local treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without... 
More about the company
Notations Surperformance© of Nanobiotix
Trading Rating : Investor Rating : -
More Ratings
All news about NANOBIOTIX
09:47aNANOBIOTIX : provides update on global clinical development plan for first-in-cl..
AQ
10/26NANOBIOTIX : Announces Third quarter 2020 Revenue
AQ
10/26NANOBIOTIX : provides update on global clinical development plan for first-in-cl..
PU
10/26NANOBIOTIX : Provides Updates on Global Clinical Development Plan for First-in-c..
BU
10/23NANOBIOTIX : announces third quarter 2020 revenue
PU
10/23NANOBIOTIX : Announces Third Quarter 2020 Revenue
BU
10/21NANOBIOTIX : Announces Four Presentations at the Society for Immunotherapy of Ca..
AQ
10/20NANOBIOTIX : Announces Four Presentations at The Society for Immunotherapy of Ca..
BU
10/14NANOBIOTIX : announces first patient injected with NBTXR3 in pancreatic cancer a..
AQ
10/13NANOBIOTIX : announces first patient injected with NBTXR3 in pancreatic cancer a..
PU
10/13NANOBIOTIX : Announces First Patient Injected with NBTXR3 in Pancreatic Cancer a..
BU
09/04NANOBIOTIX : Announces Half-year Financial Statements as at June 30, 2020
BU
09/04NANOBIOTIX : Half-year results
CO
09/01NANOBIOTIX : half-yearly earnings release
08/05DÉCLARATION MENSUELLE DU NOMBRE D'AC : Juillet 2020
PU
More news
News in other languages on NANOBIOTIX
10/26NANOBIOTIX : vers une IPO au Nasdaq
10/26Les valeurs à suivre aujourd'hui à la Bourse de Paris Lundi 26 octobre 2020
10/26Seconde vague
10/26NANOBIOTIX : le développement de NBTXR3 se poursuit
10/26EN DIRECT DES MARCHES : Europcar, Gecina, Sopra Steria, GL Events, Cellnex, SAP,..
More news
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 23,13 €
Last Close Price 6,28 €
Spread / Highest target 569%
Spread / Average Target 268%
Spread / Lowest Target 67,2%
EPS Revisions
Managers
NameTitle
Laurent Lťvy Chief Executive Officer
Laurent Condomine Chairman-Supervisory Board
Alain Dostie Chief Operating Officer
Philippe Mauberna Chief Financial Officer
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
NANOBIOTIX-24.15%193
LONZA GROUP AG62.63%47 039
SEAGEN INC.71.39%34 074
IQVIA HOLDINGS INC.4.96%31 092
CELLTRION, INC.32.04%28 087
MODERNA, INC.259.10%27 716